Fig 2: The correlation analysis of DNAJC10 expression and immunity(A) The heatmap showed the immune infiltration and function levels distribution according to the DNAJC10 expression level from low to high. (B–E) The violin plots showed that higher DNAJC10 expression was associated with higher immune score (B), stromal score (C), TMB (D) and CNA burden (E). (F) Comparison analysis of 12 ICPGs between low- and high-DNAJC10 expression gliomas. ns P>0.05; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.

Fig 3: DNAJC10 is an independent prognostic factor in gliomas(A) Univariate and multivariate Cox regression results of DNAJC10 and other clinicopathological factors of glioma patients. (B) Establishment of the DNAJC10-based nomogram model. (C–E) 1/3/5-year OS calibration curves indicate the predictive robustness of the DNAJC10-based nomogram prognostic model in the TCGA (C), CGGAseq1 (D) and CGGAseq2 (E) glioma cohorts.

Fig 4: DNAJC10 is overexpressed in gliomas(A) Boxplots of the unbalanced DNAJC10 expression levels between NBT (GTEx dataset) and gliomas (TCGA dataset) were obtained from the GEPIA website. (B) All seven kinds of cells were marked according to the annotations of published work, and the expression distribution of DNAJC10 in scRNA-seq data is represented (the color from blue to red indicate the expression level increasing). (C) The violin plot and dot plot indicated that DNAJC10 was highly expressed in a big part of GBM cells and a small part of immune cells. (D) TISCH web analysis of DNAJC10 in glioma scRNA data. (E) The protein distribution of DNAJC10 in U87 cells. (F–G) Protein expression comparisons between immunohistochemical specimens of DNAJC10 in glioma (data obtained from the Human Protein Atlas database). (H) Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) to quantify the mRNA expression levels of 12 clinical samples. (I) Western blot assay was used to quantify the DNAJC10 protein levels of 12 clinical samples. ns, P>0.05; *P<0.05; **P<0.01; ***P<0.001.

Fig 5: High DNAJC10 expression indicates poor prognosis of glioma patients(A–C) Kaplan–Meier survival curves indicated that glioma patients with higher DNAJC10 expression level showed shorter survival time and rate in three independent glioma cohorts (TCGA, CGGAseq1 and CGGAseq2). (D–F) ROC curves showed that DNAJC10 was a robust and stable prognostic indicator in glioma patients. (G,H) The prognostic role of DNAJC10 remained strong in LGGs (G) and GBM (H).